Sage Therapeutics, Inc. (SAGE)
Jul 31, 2025 - SAGE was delisted (reason: acquired by SUPN)
8.68
-0.02 (-0.23%)
Inactive · Last trade price on Jul 30, 2025

Company Description

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines.

The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults.

Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders.

In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders.

The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011.

Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Sage Therapeutics, Inc.
Sage Therapeutics logo
CountryUnited States
Founded2010
IPO DateJul 18, 2014
IndustryBiotechnology
SectorHealthcare
Employees353
CEOBarry Greene

Contact Details

Address:
55 Cambridge Parkway
Cambridge, Massachusetts 02142
United States
Phone617 299 8380
Websitesagerx.com

Stock Details

Ticker SymbolSAGE
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001597553
CUSIP Number78667J108
ISIN NumberUS78667J1088
SIC Code2834

Key Executives

NamePosition
Barry E. GreenePresident, Chief Executive Officer and Director
Christopher BenecchiChief Operating Officer and Treasurer
Gregory ShifermanSenior Vice President, General Counsel and Secretary
Michael Quirk Ph.D.Chief Scientific Officer and Interim Head of Research & Development
Ashley KaplowitzDirector of Investor Relations
Pamela HerbsterSenior Vice President and Chief People and Experience Officer
Dr. Helen ColquhounSenior Vice President of Drug Safety and Pharmacovigilance
Dr. Aaron Koenig M.D.Medical Director of Early Clinical Development
Helen RubinsteinInvestor Relations Officer

Latest SEC Filings

DateTypeTitle
Jul 31, 202525-NSEFiling
Jul 31, 2025SC 14D9/AFiling
Jul 31, 20258-KCurrent Report
Jul 31, 2025SC TO-T/AFiling
Jul 30, 2025SCHEDULE 13D/AFiling
Jul 30, 202510-QQuarterly Report
Jul 30, 20258-KCurrent Report
Jul 29, 2025SCHEDULE 13G/AFiling
Jul 28, 2025SC 14D9/AFiling
Jul 28, 2025SC TO-T/AFiling